Tags

Type your tag names separated by a space and hit enter

Pharmacological disruption of hair follicle pigmentation by cyclophosphamide as a model for studying the melanocyte response to and recovery from cytotoxic drug damage in situ.
J Invest Dermatol. 1996 Jun; 106(6):1203-11.JI

Abstract

Here we show that cyclophosphamide induces disruption of follicular melanogenesis, which is characterized by abnormal transfer of pigment granules to ectopic hair bulb locations, extrafollicular melanin incontinence, disordered formation of melanosomes, and inhibition of melanosome transfer into precortical keratinocytes. This is in contrast to dexamethasone-induced termination of follicle melanogenesis, which activates premature but predominantly normal catagen development. Cyclophosphamide-induced pigmentation disruption was accompanied by significant alterations of biochemical and biophysical markers of melanogenesis, compared to control mice treated either with vehicle or with topical dexamethasone. Electron paramagnetic resonance spectroscopy shows a decline in the melanin signal and predominant eumelanin production. Tyrosine hydroxylase activity of tyrosinase and dihydroxyphenylalanine oxidation drop rapidly, while DOPAchrome tautomerase activity increases and dihydroxyindole carboxylic acid conversion factor activity remains unchanged in cyclophosphamide-treated mice compared to controls. These observations emphasize the key role of tyrosinase as opposed to postdihydroxyphenylalanine oxidase steps in normal and pathological termination of melanogenesis and shows that tyrosinase is the most sensitive target of the melanogenic apparatus for pharmacological regulation. Follicle pigmentation recovers only during the subsequent hair cycle, i.e., after a new anagen hair bulb has been constructed, which points to the existence of a relatively chemoresistant melanoblast-like cell population residing in the noncycling part of the hair follicle.

Authors+Show Affiliations

Department of Pathology and Laboratory Medicine, Albany Medical College, New York 12208, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

8752658

Citation

Slominski, A, et al. "Pharmacological Disruption of Hair Follicle Pigmentation By Cyclophosphamide as a Model for Studying the Melanocyte Response to and Recovery From Cytotoxic Drug Damage in Situ." The Journal of Investigative Dermatology, vol. 106, no. 6, 1996, pp. 1203-11.
Slominski A, Paus R, Plonka P, et al. Pharmacological disruption of hair follicle pigmentation by cyclophosphamide as a model for studying the melanocyte response to and recovery from cytotoxic drug damage in situ. J Invest Dermatol. 1996;106(6):1203-11.
Slominski, A., Paus, R., Plonka, P., Handjiski, B., Maurer, M., Chakraborty, A., & Mihm, M. C. (1996). Pharmacological disruption of hair follicle pigmentation by cyclophosphamide as a model for studying the melanocyte response to and recovery from cytotoxic drug damage in situ. The Journal of Investigative Dermatology, 106(6), 1203-11.
Slominski A, et al. Pharmacological Disruption of Hair Follicle Pigmentation By Cyclophosphamide as a Model for Studying the Melanocyte Response to and Recovery From Cytotoxic Drug Damage in Situ. J Invest Dermatol. 1996;106(6):1203-11. PubMed PMID: 8752658.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacological disruption of hair follicle pigmentation by cyclophosphamide as a model for studying the melanocyte response to and recovery from cytotoxic drug damage in situ. AU - Slominski,A, AU - Paus,R, AU - Plonka,P, AU - Handjiski,B, AU - Maurer,M, AU - Chakraborty,A, AU - Mihm,M C,Jr PY - 1996/6/1/pubmed PY - 2001/3/28/medline PY - 1996/6/1/entrez SP - 1203 EP - 11 JF - The Journal of investigative dermatology JO - J Invest Dermatol VL - 106 IS - 6 N2 - Here we show that cyclophosphamide induces disruption of follicular melanogenesis, which is characterized by abnormal transfer of pigment granules to ectopic hair bulb locations, extrafollicular melanin incontinence, disordered formation of melanosomes, and inhibition of melanosome transfer into precortical keratinocytes. This is in contrast to dexamethasone-induced termination of follicle melanogenesis, which activates premature but predominantly normal catagen development. Cyclophosphamide-induced pigmentation disruption was accompanied by significant alterations of biochemical and biophysical markers of melanogenesis, compared to control mice treated either with vehicle or with topical dexamethasone. Electron paramagnetic resonance spectroscopy shows a decline in the melanin signal and predominant eumelanin production. Tyrosine hydroxylase activity of tyrosinase and dihydroxyphenylalanine oxidation drop rapidly, while DOPAchrome tautomerase activity increases and dihydroxyindole carboxylic acid conversion factor activity remains unchanged in cyclophosphamide-treated mice compared to controls. These observations emphasize the key role of tyrosinase as opposed to postdihydroxyphenylalanine oxidase steps in normal and pathological termination of melanogenesis and shows that tyrosinase is the most sensitive target of the melanogenic apparatus for pharmacological regulation. Follicle pigmentation recovers only during the subsequent hair cycle, i.e., after a new anagen hair bulb has been constructed, which points to the existence of a relatively chemoresistant melanoblast-like cell population residing in the noncycling part of the hair follicle. SN - 0022-202X UR - https://www.unboundmedicine.com/medline/citation/8752658/Pharmacological_disruption_of_hair_follicle_pigmentation_by_cyclophosphamide_as_a_model_for_studying_the_melanocyte_response_to_and_recovery_from_cytotoxic_drug_damage_in_situ_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0022-202X(15)42587-4 DB - PRIME DP - Unbound Medicine ER -